vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and IDACORP INC (IDA). Click either name above to swap in a different company.
IDACORP INC is the larger business by last-quarter revenue ($360.1M vs $281.3M, roughly 1.3× Guardant Health, Inc.). IDACORP INC runs the higher net margin — 12.1% vs -45.7%, a 57.8% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -4.2%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-216.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -7.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
IDACORP, Inc is an electricity holding company, incorporated in Idaho with headquarters in Boise. It comprises Idaho Power Company, IDACORP Financial and Ida-West Energy. It was formed on October 1, 1998.
GH vs IDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $360.1M |
| Net Profit | $-128.5M | $43.6M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 14.9% |
| Net Margin | -45.7% | 12.1% |
| Revenue YoY | 39.4% | -4.2% |
| Net Profit YoY | -15.8% | 15.1% |
| EPS (diluted) | $-1.01 | $0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $360.1M | ||
| Q3 25 | $265.2M | $526.4M | ||
| Q2 25 | $232.1M | $449.3M | ||
| Q1 25 | $203.5M | $411.1M | ||
| Q4 24 | $201.8M | $375.9M | ||
| Q3 24 | $191.5M | $532.5M | ||
| Q2 24 | $177.2M | $442.6M | ||
| Q1 24 | $168.5M | $417.9M |
| Q4 25 | $-128.5M | $43.6M | ||
| Q3 25 | $-92.7M | $124.4M | ||
| Q2 25 | $-99.9M | $95.8M | ||
| Q1 25 | $-95.2M | $59.6M | ||
| Q4 24 | $-111.0M | $37.9M | ||
| Q3 24 | $-107.8M | $113.6M | ||
| Q2 24 | $-102.6M | $89.5M | ||
| Q1 24 | $-115.0M | $48.2M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 14.9% | ||
| Q3 25 | -37.3% | 27.5% | ||
| Q2 25 | -45.9% | 22.4% | ||
| Q1 25 | -54.6% | 13.4% | ||
| Q4 24 | -62.4% | 11.0% | ||
| Q3 24 | -61.3% | 25.1% | ||
| Q2 24 | -56.8% | 23.3% | ||
| Q1 24 | -59.2% | 11.9% |
| Q4 25 | -45.7% | 12.1% | ||
| Q3 25 | -35.0% | 23.6% | ||
| Q2 25 | -43.0% | 21.3% | ||
| Q1 25 | -46.8% | 14.5% | ||
| Q4 24 | -55.0% | 10.1% | ||
| Q3 24 | -56.3% | 21.3% | ||
| Q2 24 | -57.9% | 20.2% | ||
| Q1 24 | -68.2% | 11.5% |
| Q4 25 | $-1.01 | $0.78 | ||
| Q3 25 | $-0.74 | $2.26 | ||
| Q2 25 | $-0.80 | $1.76 | ||
| Q1 25 | $-0.77 | $1.10 | ||
| Q4 24 | $-0.90 | $0.72 | ||
| Q3 24 | $-0.88 | $2.12 | ||
| Q2 24 | $-0.84 | $1.71 | ||
| Q1 24 | $-0.94 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $215.7M |
| Total DebtLower is stronger | $1.5B | $3.3B |
| Stockholders' EquityBook value | $-99.3M | $3.6B |
| Total Assets | $2.0B | $10.2B |
| Debt / EquityLower = less leverage | — | 0.93× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $215.7M | ||
| Q3 25 | $580.0M | $333.2M | ||
| Q2 25 | $629.1M | $474.5M | ||
| Q1 25 | $698.6M | $634.5M | ||
| Q4 24 | $525.5M | $368.9M | ||
| Q3 24 | $585.0M | $427.9M | ||
| Q2 24 | $933.7M | $169.6M | ||
| Q1 24 | $1.0B | $157.6M |
| Q4 25 | $1.5B | $3.3B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $3.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $3.6B | ||
| Q3 25 | $-354.5M | $3.5B | ||
| Q2 25 | $-305.5M | $3.4B | ||
| Q1 25 | $-250.8M | $3.3B | ||
| Q4 24 | $-139.6M | $3.3B | ||
| Q3 24 | $-60.1M | $3.3B | ||
| Q2 24 | $-1.6M | $3.2B | ||
| Q1 24 | $68.3M | $2.9B |
| Q4 25 | $2.0B | $10.2B | ||
| Q3 25 | $1.3B | $10.1B | ||
| Q2 25 | $1.3B | $9.9B | ||
| Q1 25 | $1.3B | $9.6B | ||
| Q4 24 | $1.5B | $9.2B | ||
| Q3 24 | $1.5B | $9.1B | ||
| Q2 24 | $1.6B | $8.7B | ||
| Q1 24 | $1.7B | $8.3B |
| Q4 25 | — | 0.93× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.92× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $137.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $-216.2M |
| FCF MarginFCF / Revenue | -19.3% | -60.0% |
| Capex IntensityCapex / Revenue | 9.9% | 98.3% |
| Cash ConversionOCF / Net Profit | — | 3.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-577.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $137.8M | ||
| Q3 25 | $-35.4M | $162.8M | ||
| Q2 25 | $-60.3M | $176.9M | ||
| Q1 25 | $-62.7M | $124.3M | ||
| Q4 24 | $-64.5M | $136.4M | ||
| Q3 24 | $-51.1M | $201.9M | ||
| Q2 24 | $-94.0M | $146.4M | ||
| Q1 24 | $-30.3M | $109.7M |
| Q4 25 | $-54.2M | $-216.2M | ||
| Q3 25 | $-45.8M | $-127.9M | ||
| Q2 25 | $-65.9M | $-156.4M | ||
| Q1 25 | $-67.1M | $-77.0M | ||
| Q4 24 | $-83.4M | $-48.9M | ||
| Q3 24 | $-55.3M | $-16.1M | ||
| Q2 24 | $-99.1M | $-199.6M | ||
| Q1 24 | $-37.2M | $-150.3M |
| Q4 25 | -19.3% | -60.0% | ||
| Q3 25 | -17.3% | -24.3% | ||
| Q2 25 | -28.4% | -34.8% | ||
| Q1 25 | -33.0% | -18.7% | ||
| Q4 24 | -41.3% | -13.0% | ||
| Q3 24 | -28.9% | -3.0% | ||
| Q2 24 | -55.9% | -45.1% | ||
| Q1 24 | -22.1% | -36.0% |
| Q4 25 | 9.9% | 98.3% | ||
| Q3 25 | 3.9% | 55.2% | ||
| Q2 25 | 2.4% | 74.2% | ||
| Q1 25 | 2.2% | 49.0% | ||
| Q4 24 | 9.4% | 49.3% | ||
| Q3 24 | 2.2% | 41.0% | ||
| Q2 24 | 2.9% | 78.2% | ||
| Q1 24 | 4.1% | 62.2% |
| Q4 25 | — | 3.16× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | — | 1.85× | ||
| Q1 25 | — | 2.08× | ||
| Q4 24 | — | 3.60× | ||
| Q3 24 | — | 1.78× | ||
| Q2 24 | — | 1.63× | ||
| Q1 24 | — | 2.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
IDA
| Retailrevenues | $323.0M | 90% |
| Transmissionserviceswheeling | $18.6M | 5% |
| Energyefficiencyprogramrevenues | $11.7M | 3% |
| Wholesaleenergysales | $10.5M | 3% |
| Otherrevenues | $9.5M | 3% |
